Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CTSA | P10619 | 1/20 | 0.49 |
| ▸ | PPID | Q08752 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26571804 | 0.86 | HIF1A (0.63) | EGLN1HIF1AHPGDMAPTMEN1 | |
| SCHEMBL31724716 | 0.85 | EGLN1 (0.59) | EGLN1HIF1ACTSAMAPT | |
| SCHEMBL71677 | 0.82 | HPGD (0.48) | EGLN1HPGDPPIDMAPTMEN1 | |
| SCHEMBL69286 | 0.82 | EGLN1 (0.81) | EGLN1HIF1ACTSA | |
| SCHEMBL14876209 | 0.82 | HIF1A (0.60) | EGLN1HIF1ACTSA | |
| SCHEMBL71818 | 0.81 | RAB9A (0.66) | HPGDPPIDMAPTMEN1KMT2A | |
| SCHEMBL28539032 | 0.79 | CYP1A2 (0.51) | HIF1AHPGDMAPTMEN1KMT2A | |
| SCHEMBL27039815 | 0.79 | SMN1; SMN2 (0.57) | EGLN1HPGDKMT2ARAB9ARXFP1 | |
| SCHEMBL29601352 | 0.79 | SMN1; SMN2 (0.57) | EGLN1HPGDKMT2ARAB9ARXFP1 | |
| SCHEMBL14875731 | 0.79 | HIF1A (0.56) | EGLN1HIF1ACTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| EP-2268143-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | EGLN1 448/4885HIF1A 1520/4885HPGD 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.